

Real-Life Oncology

Case-Based Discussions on the Biopsychosocial Management of Patients with Multiple Myeloma

Select Publications

- Palumbo AP, Anderson K. **Multiple Myeloma.** *N Engl J Med* 2011;364(11):1046-60. No abstract available
- Lonial S et al. **Exploring the clinical decisions of US community-based oncologists and hematologists in the management of multiple myeloma and follicular lymphoma.** *Oncology* 2010;24(12 Suppl 5):8-14.
- Randomized trial of lenalidomide, bortezomib, dexamethasone vs high-dose treatment with SCT in MM patients up to age 65 (IFM/DFCI2009). NCT01208662
- Attal M et al. **Maintenance treatment with lenalidomide after transplantation for myeloma: Final analysis of the IFM 2005-02.** *Proc ASH* 2010;Abstract 310.
- Attal M et al. **Maintenance treatment with lenalidomide after transplantation for myeloma: Analysis of secondary malignancies within the IFM 2005-02 trial.** *Proc 13th IMW* 2011;Abstract.
- McCarthy PL et al. **Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AH SCT) for multiple myeloma: CALGB 100104.** *Proc ASH* 2010;Abstract 37.
- McCarthy P et al. **Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104.** *Proc 13th IMW* 2011;Abstract.
- Quach H et al. **Managing multiple myeloma in the elderly: Are we making progress?** *Expert Rev Hematol* 2011;4(3):301-15. Abstract
- Temel JS et al. **Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial.** *Proc ASCO* 2010;Abstract 7509.
- Bertolotti P et al. **Management of side effects of novel therapies for multiple myeloma: Consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board.** *Clin J Oncol Nurs* 2008;12(3 Suppl):9-12. Abstract
- Palumbo A et al. **A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients.** *Proc ASCO* 2009;Abstract 8515.
- Moreau P et al. **Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study.** *Lancet Oncol* 2011;12(5):431-40. Abstract
- Moreau P et al. **A phase 3 prospective randomized international study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma.** *Proc ASH* 2010;Abstract 312.
- Morgan GJ et al. **First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial.** *Lancet* 2010;376(9757):1989-99. Abstract
- Potrata B et al. **Understanding distress and distressing experiences in patients living with multiple myeloma: An exploratory study.** *Psychooncology* 2011;20(2):127-34. Abstract
- Molassiotis A et al. **Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners.** *Psychooncology* 2011;20(1):88-97. Abstract